Influenza vaccination (FV) is recommended for patients with cancer. Recent data suggested that the administration of the FV was associated with an increase in immune-related adverse events (irAEs) among patients on immune checkpoint inhibitors (ICIs). Myocarditis is an uncommon but serious complication of ICIs and may also result from infection with influenza. There are no data testing the relationship between FV and the development of myocarditis on ICIs.

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors / Awadalla, Magid; Golden, Doll Lauren Alexandra; Mahmood, Syed S; Alvi, Raza M; Mercaldo, Nathaniel D; Hassan, Malek Z O; Banerji, Dahlia; Rokicki, Adam; Mulligan, Connor; Murphy, Sean P T; Jones-O'Connor, Maeve; Cohen, Justine V; Heinzerling, Lucie M; Armanious, Merna; Sullivan, Ryan J; Damrongwatanasuk, Rongras; Chen, Carol L; Gupta, Dipti; Kirchberger, Michael C; Moslehi, Javid J; Shah, Sachin P; Ganatra, Sarju; Thavendiranathan, Paaladinesh; Rizvi, Muhammad A; Sahni, Gagan; Lyon, Alexander R; Tocchetti, Carlo G; Mercurio, Valentina; Thuny, Franck; Ederhy, Stephane; Mahmoudi, Michael; Lawrence, Donald P; Groarke, John D; Nohria, Anju; Fradley, Michael G; Reynolds, Kerry L; Neilan, Tomas G. - In: JOURNAL FOR IMMUNOTHERAPY OF CANCER. - ISSN 2051-1426. - 7:1(2019), p. 53. [10.1186/s40425-019-0535-y]

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors

Tocchetti, Carlo G;Mercurio, Valentina;
2019

Abstract

Influenza vaccination (FV) is recommended for patients with cancer. Recent data suggested that the administration of the FV was associated with an increase in immune-related adverse events (irAEs) among patients on immune checkpoint inhibitors (ICIs). Myocarditis is an uncommon but serious complication of ICIs and may also result from infection with influenza. There are no data testing the relationship between FV and the development of myocarditis on ICIs.
2019
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors / Awadalla, Magid; Golden, Doll Lauren Alexandra; Mahmood, Syed S; Alvi, Raza M; Mercaldo, Nathaniel D; Hassan, Malek Z O; Banerji, Dahlia; Rokicki, Adam; Mulligan, Connor; Murphy, Sean P T; Jones-O'Connor, Maeve; Cohen, Justine V; Heinzerling, Lucie M; Armanious, Merna; Sullivan, Ryan J; Damrongwatanasuk, Rongras; Chen, Carol L; Gupta, Dipti; Kirchberger, Michael C; Moslehi, Javid J; Shah, Sachin P; Ganatra, Sarju; Thavendiranathan, Paaladinesh; Rizvi, Muhammad A; Sahni, Gagan; Lyon, Alexander R; Tocchetti, Carlo G; Mercurio, Valentina; Thuny, Franck; Ederhy, Stephane; Mahmoudi, Michael; Lawrence, Donald P; Groarke, John D; Nohria, Anju; Fradley, Michael G; Reynolds, Kerry L; Neilan, Tomas G. - In: JOURNAL FOR IMMUNOTHERAPY OF CANCER. - ISSN 2051-1426. - 7:1(2019), p. 53. [10.1186/s40425-019-0535-y]
File in questo prodotto:
File Dimensione Formato  
2019 awadalla jic s40425-019-0535-y.pdf

solo utenti autorizzati

Licenza: Accesso privato/ristretto
Dimensione 686.14 kB
Formato Adobe PDF
686.14 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/741371
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 54
  • ???jsp.display-item.citation.isi??? 51
social impact